Headache associated with SGLT2i was previously reported in a multicenter retrospective descriptive analysis evaluating Kaiser Permanente Southern California members with type 2 diabetes and chronic kidney disease 1, 2, or 3 who first filled an SGLT2 inhibitor prescription [26]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.